JAGX
Jaguar Health, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "54eff64d-15d4-4f99-88d1-7110bcbfdcd2",
"title": "Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe By Inves",
"description": "Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe",
"keywords": "",
"snippet": "Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and ...",
"url": "https://www.investing.com/news/press-releases/jaguar-health-announces-submission-of-clinical-trial-applications-for-crofelemer-for-the-rare-disease-indications-microvillus-inclusion-disease-mvid-and-short-bowel-syndrome-sbs-in-europe-93CH-3432132",
"image_url": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
"language": "en",
"published_at": "2024-05-09T14:48:05.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "JAGX",
"name": "Jaguar Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 63.865837,
"sentiment_score": 0.138133,
"highlights": [
{
"highlight": "Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS\n\nSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / <em>Jaguar</em> <em>Health</em>, <em>Inc</em>.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:JAGX</em>) (\"Jaguar\") today announced that Jaguar family companies Napo Pharmaceuticals (\"Napo\") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German health authorities to initiate a phase 2 clinical trial of Jaguar's novel plant-based prescription drug crofelemer for treatment of short bowel syndrome",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "About the <em>Jaguar</em> <em>Health</em> Family of Companies\n\n<em>Jaguar</em> <em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "See disclosureor\n\nFor more information about:\n\n<em>Jaguar</em> <em>Health</em>, visit https://jaguar.health\n\nNapo Pharmaceuticals, visit www.napopharma.com\n\nNapo Therapeutics, visit napotherapeutics.com\n\nMagdalena Biosciences, visit magdalenabiosciences.com\n\nVisit Jaguar on LinkedIn: https://www.linkedin.com/company/<em>jaguar</em>-<em>health</em>/\n\nVisit Jaguar on X: https://twitter.com",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Contact:\n\[email protected]\n\nJaguar-JAGX\n\nSOURCE: <em>Jaguar</em> <em>Health</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Jaguar</em> <em>Health</em> Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe By Inves",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "JAGX",
"total_documents": 1,
"sentiment_avg": 0.1381330043077469
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us